Presentation and Webcast on Monday, January 12, 2015 at 8:30 a.m.
Pacific Time/11:30 a.m. Eastern Time
ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical
company focused on developing and commercializing first-in-class, oral
low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies
for the treatment of hypercholesterolemia and other cardiometabolic risk
markers, today announced that president and chief executive officer, Tim
M. Mayleben, will present at the 33rd Annual J.P. Morgan
Healthcare Conference in San Francisco, CA on Monday, January 12, 2015
at 8:30 a.m. Pacific Time/11:30 a.m. Eastern Time.
A live, listen-only webcast of the presentation can be accessed on the
investor relations section of the Esperion website at www.esperion.com.
A webcast replay of the presentation will be available approximately one
hour after completion and will be archived on the Company's website for
90 days following the event.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with
cardiometabolic diseases. The Esperion team leverages its understanding
of, and experience with, key biological pathways to discover and develop
innovative therapies for the treatment of patients with
hypercholesterolemia who have uncontrolled cholesterol levels despite
the use of currently available therapies. Esperion has assembled a
portfolio of programs including one product candidate in late-stage
clinical evaluation (ETC-1002) and two pre-clinical product candidates.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is an emerging pharmaceutical company
focused on developing and commercializing first-in-class, oral,
LDL-cholesterol lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower LDL-cholesterol
levels and avoid the side effects associated with therapies currently
available for lowering LDL-cholesterol. ETC-1002 is being developed for
patients with hypercholesterolemia, including those with a history of
statin intolerance. For more information, please visit www.esperion.com
and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com
Investor
Contact:
Esperion Therapeutics, Inc.
Mindy Lowe, 734.887.3903
mlowe@esperion.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media